Abstract
Purpose. To investigate the efficacy and safety of 360° selective laser trabeculoplasty (SLT) on medically uncontrolled open-angle glaucoma (OAG) and to evaluate the effects of antiglaucomatous medications on the results of therapy. Materials and Methods. The medical records of 62 eyes of 51 patients with OAG, which did not reach the targeted intraocular pressure (IOP) with maximum antiglaucomatous medical therapy, were retrospectively reviewed. Results. A statistically significant decrease was observed in the mean baseline IOP at 1, 3, 6, and 12 months of followup (P < 0.01). The success rate was 64.5% in all of the patients. The success rates did not vary significantly by taking 1, 2, 3, or 4 medications with the rates of 63.6%, 71.4%, 64.2%, and 58.3% (P = 0.06). The success rate of eyes on medication more or less than 6 months was 62.5% or 66.7%, respectively (P = 0.3). There was a positive correlation between mean baseline IOP and mean reduction in IOP from baseline (P < 0.001, r = 0.8). Conclusion. Application of 360° of SLT provided an effective and safe IOP reduction in medically uncontrolled OAG. Baseline IOP was found to be the most important factor in the efficacy of therapy.
Highlights
Several studies have corroborated the efficacy and safety of selective laser trabeculoplasty (SLT) since its rst description in 1995 by Latina and Park [1]
Success rates and levels of reported intraocular pressure (IOP) reduction vary between studies, a great number of studies show that it is a safe procedure with low complication rates [5,6,7]. is heterogeneity could be explained by differences in the samples, outcomes, and treatment protocols such as power, spot numbers, and the degree of angle treated
E aims of this study were to investigate the safety and efficacy of 360∘ SLT application in patients with open-angle glaucoma (OAG) who were not well controlled with maximal medical therapy and to evaluate the factors that could in uence the results including the number and type of antiglaucomatous medications, duration of medical therapy, and baseline IOP
Summary
Several studies have corroborated the efficacy and safety of selective laser trabeculoplasty (SLT) since its rst description in 1995 by Latina and Park [1]. Selective laser trabeculoplasty, which uses a 532 nm frequency-doubled, Qswitched Nd:YAG laser, is thought to selectively stimulate the pigmented trabecular meshwork cells and facilitate improved aqueous out ow in open-angle glaucoma (OAG) [2]. Selective laser therapy can be used as a rst-line therapy, alternative to medical therapy, or as an adjunctive therapy to topical glaucoma drops [3, 4]. E aims of this study were to investigate the safety and efficacy of 360∘ SLT application in patients with OAG who were not well controlled with maximal medical therapy and to evaluate the factors that could in uence the results including the number and type of antiglaucomatous medications, duration of medical therapy, and baseline IOP
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have